Sanofi and Teva announce exclusive collaboration to deliver inflammatory bowel disease treatment

Sanofi (EURONEXT: SAN and NASDAQ: SNY) and Teva Pharmaceuticals, a U.S. subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announce today a collaboration to co-develop and co-commercialize asset TEV’574, currently in Phase 2b clinical trials for the treatment of Ulcerative Colitis and Crohn’s Disease, two types of inflammatory bowel disease.

What do Parkinson’s and obesity have in common?

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. STAT is

June 12, 2024

DEA Approves Ayahuasca Import for Religious Use

The TDR Three Key Takeaways regarding Ayahuasca and DEA: Ayahuasca’s role in religious practices gains recognition by the DEA. DEA acknowledges ayahuasca’s role in Native

April 23, 2024

Metrion Biosciences appoints Dr Chris Mathes as Chief Commercial Officer

Metrion Biosciences Ltd (“Metrion”), the specialist preclinical contract research organization (CRO) and a leader in ion channel screening, today announced the appointment of Dr Chris

July 24, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.